Urinschnelltests (Immunoassays) auf Drogen und Medikamente ...

Urinschnelltests (Immunoassays) auf Drogen und Medikamente
Wissenswertes für den Arzt
Recherche de drogues et de médicaments par tests rapides d’urine
(immuno-essais)
Informations utiles pour les médecins
Literatur / Références
1. Reisfield GM, Webb FJ, Bertholf RL, Sloan PA,Wilson GR. Family physicians' proficiency in urine drug test
interpretation. J Opioid Manag. 2007;3(6):333–7.
2. Reisfield GM, Bertholf R, Barkin RL, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J
Opioid Manag. 2007;3(2):80–6.
3. George S, Braithwaite RA. Use of on-site testing for drugs of abuse. Clin Chem. 2002;48(10):1639–46.
4. Schütz H. Drogenscreening mit Immunoassays. Pharmazie in unserer Zeit. 1999;28(6):320–8.
5. Klipfel D, Müller D, Sooth W, Walther A. Leitfaden Drogenerkennung – Drogenvortests und Anfangsverdacht in der
Unfallaufnahme und Verkehrsüberwachung. 1st ed. Bonn: Kirschbaum Verlag; 2009.
6. Swiss Guidelines Committee for Drugs of Abuse Testing SCDAT. Richtlinien für die Suchtstoffanalytik (Vers DE
2012–11–15). [cited 2012 Dez 10]. Available from: www.scdat.ch.
7. Moeller KE, Lee KC,Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–
76.
8. Standbridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician.
2010;81(5):635–40.
9. Vincent EC, Zebelman A, Goodwin C. What common substances can cause false positives on urine screens for drugs
of abuse? J Fam Pract. 2006;55(10): 893–4, 897.
10. Brahm NC, Yeager LL, Fox MD, Farmer KC,Palmer TA. Commonly prescribed medications and potential falsepositive
urine drug screens. Am J Health Syst Pharm. 2010;67(16):1344–50.
11. Schütz H, Paine A, Erdmann F, Weiler G, Verhoff MA. Immunoassays for drug screening in urine: chances,
challenges, and pitfalls. Forensic Sci Med Pathol. 2006;2(2):75–83.
12. Schwartz, RH. Urine testing in the detection of drugs of abuse. Arch Intern Med. 1988;148(11):2407–12.
13. Tenore PL. Advanced urine toxicology testing. J Addict Dis. 2010;29(4):436–48.
14. Jaffee WB, Trucco E, Levy S,Weiss RD. Is the urine really negative? A systematic review of tampering methods in
urine drug screening and testing. J Subst Abuse Treat. 2007;33(1):33–42.
15. Skopp G, Pötsch L, Becker J, Röhrich J, Mattern R. Zur präanalytischen Phase chemisch-toxikologischer
Untersuchungen – I. Immunochemisches Drogenscreening im Urin – Erkennbarkeit von Manipulationen und
Strategien bei rechtsmedizinischer Fragestellung. Rechtsmedizin. 1998;8:163–7.
16. Schwarzhoff R, Cody JT. The effects of adulterating agents on FPIA analysis of urine for drugs of abuse. J Anal
Toxicol. 1993;17(1):14–7.
17. Morland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T. Cannabinoids in blood and urine after passive
inhalation of cannabis smoke. J Forensic Sci. 1985;30(4):997–1002.
18. Perez-Reyes M, Di Guiseppi S, Mason AP, Davis KH. Passive inhalation of marihuana smoke and urinary excretion of
cannabinoids. Clin Pharmacol Ther. 1983;34(1):36–41.
19. Law B, Mason PA, Moffat AC, King LJ, Marks V. Passive inhalation of cannabis smoke. J Pharm Pharmacol.
1984;36(9): 578–81.
20. Cone EJ, Johnson RE, Darwin WD, Yousefnejad D, Mell LD, Paul BD et al. Passive inhalation of marijuana smoke:
urinalysis and room air levels of delta-9–tetrahydrocannabinol. J Anal Toxicol. 1987;11(3): 89–96.
1

21. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke.
Clin Pharmacol Ther. 1986;40(3):247–56.
22. Magerl H, Wiegand C,Schulz E. Cannabinoid intake by passive smoking. Arch Kriminol. 1987;179(1–2):31–7.
23. Westin AA, Slordal L. Passive inhalation of cannabis smoke – is it detectable? Tidsskr Nor Laegeforen.
2009;129(2):109–13.
24. Schimmel I, Drobnik S, Röhrich J, Becker J, Zörntlein S,Urban R. Passive Cannabisexposition unter realistischen
Bedingungen – Untersuchungen in einem Coffee-Shop. Blutalkohol. 2010;47:269–74.
25. Toennes SW, Röhrich J, Wunder C. Interpretation of blood analysis data found after passive exposure to cannabis.
Arch Kriminol. 2010;225(3–4):90–8.
26. George S, Parmar S, Meadway C, Braithwaite RA. Application and validation of a urinary methadone metabolite
(EDDP) immunoassay to monitor methadone compliance. Ann Clin Biochem. 2000;37:350–4.
27. Larson ME, Richards TM. Quantification of a methadone metabolite (EDDP) in urine: assessment of compliance. Clin
Med Res. 2009;7(4): 134–41.
28. Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal
Toxicol. 2003; 27(7):449–52.
29. Lachenmeier DW, Sproll C,Musshoff F. Poppy seed foods and opiate drug testing – where are we today? Ther Drug
Monit. 2010;32(1):1–18.
30. Jankovicova K, Ulbrich P, Fuknova M. Effect of poppy seed consummation on the positive results of opiates
screening in biological samples. Leg Med (Tokyo). 2009;11(Suppl 1):S416–8.
31. Moeller MR, Hammer K, Engel O. Poppy seed consumption and toxicological analysis of blood and urine samples.
Forensic Sci Int. 2004;143:183–6.
32. Berghaus G, Musshoff F, Madea B. Verkehrsmedizin – Fahreignung, Fahrsicherheit, Unfallrekonstruktion. 1st edition.
Köln: Deutscher Ärzte-Verlag GmbH; 2007.
2